GO
Loading...

Gilead Sciences Inc

More

  • Final Glance: Biotechnology companies Friday, 23 Jan 2015 | 6:04 PM ET

    Amgen Inc. rose$. 24 or. 2 percent, to $159.81. Biogen Idec rose $3.88 or 1.1 percent, to $357.53. Celgene Corp. rose$. 18 or. 1 percent, to $123.89.

  • Midday Glance: Biotechnology companies Friday, 23 Jan 2015 | 1:31 PM ET

    Amgen Inc. fell$. 45 or. 3 percent, to $159.12. Biogen Idec rose $4.60 or 1.3 percent, to $358.25. Celgene Corp. rose$. 04 or percent, to $123.75.

  • Early Glance: Biotechnology companies Friday, 23 Jan 2015 | 11:24 AM ET

    Amgen Inc. fell$. 51 or. 3 percent, to $159.07. Biogen Idec rose $2.25 or. 6 percent, to $355.90. Celgene Corp. fell$. 73 or. 6 percent, to $122.98.

  • Final Glance: Biotechnology companies Thursday, 22 Jan 2015 | 6:05 PM ET

    Amgen Inc. rose $2.19 or 1.4 percent, to $159.57. Biogen Idec fell $8.18 or 2.3 percent, to $353.65. Celgene Corp. rose $1.49 or 1.2 percent, to $123.71.

  • Midday Glance: Biotechnology companies Thursday, 22 Jan 2015 | 1:29 PM ET

    Amgen Inc. rose$. 42 or. 3 percent, to $157.80. Biogen Idec fell $10.37 or 2.9 percent, to $351.46. Celgene Corp. fell$. 20 or. 2 percent, to $122.02.

  • Early Glance: Biotechnology companies Thursday, 22 Jan 2015 | 12:09 PM ET

    Amgen Inc. fell $2.08 or 1.3 percent, to $155.30. Biogen Idec fell $10.44 or 2.9 percent, to $351.39. Celgene Corp. fell $1.14 or. 9 percent, to $121.08.

  • Final Glance: Biotechnology companies Wednesday, 21 Jan 2015 | 6:01 PM ET

    Amgen Inc. fell$. 22 or. 1 percent, to $157.38. Biogen Idec fell $1.46 or. 4 percent, to $361.83. Celgene Corp. fell $1.03 or. 8 percent, to $122.22.

  • Midday Glance: Biotechnology companies Wednesday, 21 Jan 2015 | 1:22 PM ET

    Amgen Inc. rose$. 05 or percent, to $157.65. Biogen Idec rose$. 13 or percent, to $363.41. Celgene Corp. fell$. 83 or. 7 percent, to $122.42.

  • Early Glance: Biotechnology companies Wednesday, 21 Jan 2015 | 10:45 AM ET

    Amgen Inc. fell$. 68 or. 4 percent, to $156.93. Biogen Idec fell $2.04 or. 6 percent, to $361.24. Celgene Corp. fell$. 82 or. 7 percent, to $122.43.

  • Final Glance: Biotechnology companies Tuesday, 20 Jan 2015 | 6:35 PM ET

    Amgen Inc. fell$. 83 or. 5 percent, to $157.60. Biogen Idec rose $10.53 or 3.0 percent, to $363.28. Celgene Corp. rose $1.44 or 1.2 percent, to $123.25.

  • Most active Nasdaq-traded stocks Tuesday, 20 Jan 2015 | 1:33 PM ET

    Advanced Micro Devices Inc. fell 6.3 percent to $2.24 with 56,007,000 shares traded. Apple Inc. rose 2.6 percent to $108.72 with 46,516,000 shares traded. Cisco Systems Inc. rose 1.4 percent to $28.07 with 33,360,500 shares traded.

  • Midday Glance: Biotechnology companies Tuesday, 20 Jan 2015 | 1:33 PM ET

    Amgen Inc. fell $2.21 or 1.4 percent, to $156.22. Biogen Idec rose $3.65 or 1.0 percent, to $356.40. Celgene Corp. fell$. 30 or. 2 percent, to $121.51.

  • Early Glance: Biotechnology companies Tuesday, 20 Jan 2015 | 10:33 AM ET

    Amgen Inc. fell $2.17 or 1.4 percent, to $156.26. Biogen Idec fell $1.29 or. 4 percent, to $351.46. Celgene Corp. fell$. 73 or. 6 percent, to $121.08.

  • Benefits firms shouldn't play drug favorites: CEO Tuesday, 20 Jan 2015 | 10:00 AM ET

    Regeneron Pharmaceuticals CEO Dr. Leonard Schleifer told CNBC on Tuesday that benefits companies should not try to practice medicine.

  • Johnson & Johnson tops 4Q earnings expectations Tuesday, 20 Jan 2015 | 8:59 AM ET

    TRENTON, N.J.— The strong dollar and stiff competition for some products squeezed Johnson& Johnson in the fourth quarter and it missed Wall Street expectations for revenue, triggering a sell-off of its shares. Hospital admissions and surgeries are increasing, which boosted sales of Johnson& Johnson's surgical devices, wound care products and medicines, the...

  • TRENTON, N.J.— Drugmaker AbbVie Inc. said Monday that its new, all-pill hepatitis C combo treatment has been approved for patients in the 28 European Union member countries. The company said the European Commission granted marketing authorization for the combination of Viekirax and Exviera. It's already approved in EU nonmembers Switzerland, Norway, Iceland...

  • SAN FRANCISCO, Jan 15- The world's biggest drugmakers face a new reality when it comes to U.S. pricing for their products as insurers use aggressive tactics to extract steep price discounts, even for the newest medications. Big Pharma executives acknowledged the depth of change this week during public presentations and interviews with Reuters at the J.P....

  • Oil, dollar to determine earnings winners, losers Wednesday, 14 Jan 2015 | 10:53 AM ET
    A CSX employee walks on a locomotive while on a siding at Worthville, Ky., Oct. 11, 2013.

    The plunge in oil and the strong dollar are the lead factors in determining stocks to buy or short as the fourth quarter earnings reports come out.

  • Navellier’s crunching finds growth for cheap Wednesday, 14 Jan 2015 | 6:00 AM ET
    Actavis Group headquarters is shown in Hafnarfjordur, Iceland, April 20, 2006.

    Louis Navellier says crunching the numbers for stocks that move independent of the market point him to two drug companies and a Chinese retailer.

  • Investors are watching closely to see how insurers decide to cover these drugs, which cost tens of thousands of dollars per treatment, after AbbVie Inc started a competitor to Gilead Sciences' breakthrough hepatitis C treatment. Express Scripts, the largest pharmacy benefit manager in the United States, dropped Gilead Sciences hepatitis C drugs from its main...